The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

Europe’s largest pharmaceutical companies are calling on the EU leadership to significantly increase the purchase and sales prices of ...

Big Pharma, long a lobbying powerhouse in Washington, is struggling to settle on a strategy for defending itself against ...

Major drugmakers were a standout on a tumultuous day of corporate earnings on Thursday, beating expectations even as they ...

In what could be seen as a bellwether for the pharmaceutical industry's sweeping shift toward localised manufacturing—spurred ...

Here’s what several large drugmakers said about tariffs when reporting earnings this morning: Merck made a small downward ...

Parcel giant UPS said on Thursday it would buy Canada's Andlauer Healthcare Group in an all-cash deal valued at $1.6 billion, ...

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca ...

Unfortunately, the same cannot be said for Europe. While it has been home to some of the most important biopharmaceutical companies in the world – many of which have consistently delivered ...

Benchmark indices ended on a negative note with the Nifty 50 slipping below the 24,300 mark and the Sensex falling by ...

Tata Consumer Products Ltd. was in focus in Thursday’s brokerage notes after the company reported its January-March earnings ...